Search Results - "Gou, Miaomiao"

PD-1 inhibitors-based second-line therapy for metastatic gastric cancer by Gou, Miaomiao, Zhang, Yong, Wang, Zhikuan, Dai, Guanghai

“…Metastatic gastric cancer (MGC) patients with progression on first-line treatment still have poor outcomes on chemotherapy. The KEYNOTE-061 study demonstrated…”
Get full text

Pretreatment platelet-to-lymphocyte ratio (PLR) as a prognosticating indicator for gastric cancer patients receiving immunotherapy by Gou, Miaomiao, Zhang, Yong

“…Background Previous investigations suggest that systemic inflammation markers are able to provide prognostic value in several cancers. This study seeks to…”
Get full text

Efficacy and safety of nivolumab for metastatic biliary tract cancer by Gou, Miaomiao, Zhang, Yong, Si, Haiyan, Dai, Guanghai

“…PD-1 inhibitors have improved efficacy in many cancers. There are currently no reports of the use of PD-1 inhibitors, such as nivolumab, for metastatic biliary…”
Get full text

Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer by Gou, Miaomiao, Qu, Tongtong, Wang, Zhikuan, Yan, Huan, Si, Yanhai, Zhang, Yong, Dai, Guanghai

“…Background and Aims. Biomarkers for systemic inflammation have been introduced into clinical practice for risk-rating in cancer patients’ treatment. This study…”
Get full text

Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy by Gou, Miaomiao, Qian, Niansong, Zhang, Yong, Wei, Lihui, Fan, Qihuang, Wang, Zhikuan, Dai, Guanghai

“…Background Immunotherapy has shown promising results for metastatic gastric cancer (MGC) patients. Nevertheless, not all patients can benefit from anti-PD-1…”
Get full text

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China by Gou, Miaomiao, Qian, Niansong, Zhang, Yong, Yan, Huan, Si, Haiyan, Wang, Zhikuan, Dai, Guanghai

“…Background Fruquintinib, a vascular endothelial growth factor receptor inhibitor, is a new anticancer drug independently developed in China to treat refractory…”
Get full text

LncRNA HEIH promotes cell proliferation, migration and invasion in cholangiocarcinoma by modulating miR-98-5p/HECTD4 by Wan, Tao, Wang, Hongguang, Gou, Miaomiao, Si, Haiyan, Wang, Zhikuan, Yan, Huan, Liu, Tiee, Chen, Shiyun, Fan, Runjia, Qian, Niansong, Dai, Guanghai

“…[Display omitted] To date, a large set of long non-coding RNAs (lncRNAs) have been identified in tumorigenesis and progression. The present study focused on…”
Get full text

PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis by Gou, Miaomiao, Zhang, Yong, Liu, Tiee, Si, Haiyan, Wang, Zhikuan, Yan, Huan, Qian, Niansong, Dai, Guanghai

“…There are limited treatment options for advanced biliary tract cancers (BTCs), including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer,…”
Get full text

The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy by Gou, Miaomiao, Zhang, Yong, Liu, Tiee, Qu, Tongtong, Si, Haiyan, Wang, Zhikuan, Yan, Huan, Qian, Niansong, Dai, Guanghai

“…Biomarkers such as prevailing PD-L1 expression and TMB have been proposed as a way of predicting the outcome of immunotherapy in patients with advanced gastric…”
Get full text

A composite indicator of derived neutrophil–lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors by Chen, Shiyun, Guo, Shiyuan, Gou, Miaomiao, Pan, Yuting, Fan, Mengjiao, Zhang, Nan, Tan, Zhaoli, Dai, Guanghai

“…Background There are currently no established biomarkers that can predict whether advanced pancreatic carcinoma (PC) patients would benefit from immune…”
Get full text

Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study by Gou, Miaomiao, Dai, Guanghai, Wang, Zhi-Kuan

“…e16373 Background: Biliary tract cancer (BTC) is a heterogeneous group of diseases with dismal prognosis. The TOPAZ-1 phase III trial and KENOTE 966 reported a…”
Get full text

PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study by Gou, Miaomiao, Zhang, Yong, Wang, Zhikuan, Qian, Niansong, Dai, Guanghai

“…Summary Background Immune checkpoint inhibitors have been approved for first- and third-line treatment of advanced gastric cancer. However, pembrolizumab alone…”
Get full text

Exploration of neoadjuvant chemotherapy and post-tumor microenvironment for advanced gastric cancer (GC) or gastroesophageal junction cancer (EGJ) by Gou, Miaomiao, Gao, Yunhe, Qiao, Zhi, Wang, Zhi-Kuan, Liu, Yi, Dai, Guanghai

“…e16099 Background: Neoadjuvant chemotherapy (NAC) is still the main strategy for operable local advanced gastric cancer (GC) or gastroesophageal junction…”
Get full text

Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer by Gou, Miaomiao, Qian, Niansong, Zhang, Yong, Wang, Zhikuan, Dai, Guanghai

“…Background The survival benefit from later-line treatment for patients with metastatic colorectal cancer (mCRC) remains disappointing. Here, in a real-world…”
Get full text

A phase II single-center single-arm study of PD-1 inhibitor in combination with albumin paclitaxel and apatinib as second-line treatment of metastatic gastric cancer (mGC) by Gou, Miaomiao, Qian, Niansong, Wang, Zhikuan, Yan, Huan, Zhang, Yong, Si, Haiyan, Dai, Guanghai

“…e16024 Background: Immune checkpoint inhibitors have been approved for first- or third-line treatment of metastatic gastric cancer. However, pembrolizumab…”
Get full text

Efficacy and safety of nivolumab in first-line or further treatment of advanced metastatic biliary tract cancer by Gou, Miaomiao, Zhang, Yong, Si, Haiyan, Dai, Guanghai

“…Abstract only 315 Background: PD-1 inhibitors have improved efficacy in many cancers. There are few report of nivolumab for metastatic biliary tract cancer…”
Get full text

Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study by Gou, Miaomiao, Si, Haiyan, Zhang, Yong, Qian, Niansong, Wang, Zhikuan, Shi, Weiwei, Dai, Guanghai

“…No definitive treatment strategy has been established for patients with metastatic colorectal cancer (mCRC) who experienced progression after three or more…”
Get full text

Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and hemoglobin (Hb) predict immunotherapy outcomes in patients with advanced or metastatic gastric cancer by Gou, Miaomiao, Zhang, Yong, Yan, Huan, Si, Haiyan, Wang, Zhikuan, Dai, Guanghai

“…Abstract only e16075 Background: This study aimed to confirm the prognostic role of pretreatment neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte…”
Get full text

Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer by Chen, Shiyun, Gou, Miaomiao, Yan, Huan, Fan, Mengjiao, Pan, Yuting, Fan, Runjia, Qian, Niansong, Dai, Guanghai

“…Background. Nowadays, PD-1/PD-L1 inhibitors are widely used to treat various malignant tumors. However, during the immunotherapy in a few patients, a flare-up…”
Get full text

Changes in the neutrophil-to-lymphocyte ratio (NLR) as predictive values for metastatic gastric cancer patients with PD-1 inhibitors by Gou, Miaomiao, Zhang, Yong, Wang, Zhikuan, Qian, Niansong

“…Background The combination of immunotherapy and chemotherapy can improve the survival of metastatic gastric cancer (MGC) patients based on checkmate 649 and…”
Get full text